PFIZER INC.

Accipiter Biosciences has emerged from stealth with $12.7 million in seed financing co-led by Takeda and Flying Fish Partners to develop de novo multifunctional biologics for complex diseases.

Biovac launched a state-of-the-art product development laboratory in Cape Town on November 6, 2025, backed by the Gates Foundation to advance Africa's vaccine manufacturing capabilities.

Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.

Pfizer received early U.S. Federal Trade Commission antitrust clearance for its proposed $7.3 billion acquisition of Metsera, more than a week ahead of the original November 7 deadline.

Hemlibra has shown efficacy in preventing bleeding during exercise for patients with Hemophilia A, marking a significant advancement in activity-related bleeding management.

The FDA announced new draft guidance to simplify biosimilar approval by reducing clinical testing requirements and shortening development timelines.

The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.

BioMarin Pharmaceutical announced plans to divest Roctavian, its hemophilia A gene therapy, after the treatment generated only $26 million in sales in 2024 versus initial projections of $100-200 million.

AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.

Moderna's mRNA-1345 RSV vaccine demonstrated safety and efficacy in a Phase III trial of 150 solid organ transplant recipients, with adverse events being mostly grade 1-2 and resolving within 2-3 days.